Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-11 02:15 • The Motley Fool Positive Axe Cap view: Selective

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

Axe note: Balancing yield and risk in big pharma stocks is essential—don’t chase high dividends without diversification.

2026-10-11 00:37 • The Motley Fool Mixed Axe Cap view: Bearish

Cerebras Systems expects $880-890 million in core revenue for 2026, comparable to Nvidia's data center business revenue of $830 million in fiscal 2017. However, the similarities end there. Unlike Nvidia, which had a profitable gaming business funding its AI expansion, Cerebras is unprofitable with negative operating margins and relies on just three customers for three-quarters of revenue. The stock trades at 44x expected revenue and is valued at two-thirds of Nvidia's entire 2016 market cap, raising questions about whether it can replicate Nvidia's growth trajectory.

Axe note: Cerebras is growing fast but lacks Nvidia’s solid foundation and profitability, raising big questions for investors.

2026-10-11 00:15 • The Motley Fool Positive Axe Cap view: Selective

The author recommends five dividend stocks currently out of favor: PepsiCo, Hormel, Hershey, McCormick, and Realty Income. Despite near-term headwinds from inflation and rising interest rates, the author believes these companies have strong fundamentals, long histories of dividend increases, and will navigate current challenges successfully. He advocates a long-term buy-and-hold approach with dividend reinvestment, ignoring short-term stock price fluctuations.

Axe note: High-quality dividend payers with long track records can offer steadiness when markets are choppy.